Mannkind Corp
MNKD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000899460
In the last 90 days, Mannkind Corp insiders filed 0 open-market purchases and 4 sales; 260 institutions reported holding it in 13F filings for Q2 2026, worth $776.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Mannkind Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 4 filings
- 2 insiders, $597.1K in total
- Insiders trading
- 2
- Net value
- −$597.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Mannkind Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Binder Steven B. | Director | 752,309 | Sep 14, 2026 | 6 |
| Prentiss Christopher B | Chief Financial Officer | 318,668 | Jul 17, 2026 | 4 |
| Marasco Dominic | Pres, Endocrine Business Unit | 343,398 | Jul 17, 2026 | 2 |
| Tross Stuart A | Chief People & Workpl Officer | 1,058,142 | Jul 17, 2026 | 6 |
| Castagna Michael | Chief Executive Officer | 2,433,779 | Jul 17, 2026 | 9 |
| Singh Sanjay R | EVP Technical Operations | 478,966 | Jul 17, 2026 | 4 |
| Thomson David | EVP Genl Counsel & Secretary | 797,554 | Jul 17, 2026 | 5 |
| Consiglio Ronald J | Director | 132,342 | May 22, 2026 | 1 |
| Mundkur Christine | Director | 254,493 | May 22, 2026 | 1 |
| Hooper Anthony C | Director | 236,153 | May 22, 2026 | 2 |
| Friedman Michael A | Director | – | May 22, 2026 | 1 |
| Shannon James Samuel | Director | 64,635 | May 22, 2026 | 2 |
| Grancio Jennifer | Director | 244,815 | May 22, 2026 | 1 |
| Kay Sabrina | Director | 265,600 | May 22, 2026 | 1 |
| Ahuja Ajay | Chief Medical Officer | 318,200 | Mar 25, 2026 | 2 |
| Blank Burkhard | EVP Chief Medical Officer | 460,791 | Jul 17, 2025 | 0 |
| Sabella Lauren M | EVP Operations | 349,841 | Jul 17, 2025 | 0 |
| Kresa Kent | Director | – | May 17, 2024 | 0 |
| Kocinsky Joseph | Chief Technology Officer | 745,233 | Aug 29, 2022 | 0 |
| Galindo Alejandro | EVP Endocrine Business Unit | 576,690 | Aug 24, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 23, 2022 (view filing) | Aug 22 | 1 day | Galindo AlejandroEVP Endocrine Business Unit | SSaleCommon Stock, $0.01 Par Value | −4.62K | $3.85 | −$17.8K | −0.6%777.1K after | 2 lots |
| Mar 1, 2022 (view filing) | Feb 28 | 1 day | Hooper Anthony CDirector | PPurchaseCommon Stock,$.01 par value | +40.0K | $2.71 | +$108.4K | +13.4%338.4K after | |
| Mar 1, 2022 (view filing) | Feb 28 | 1 day | Mundkur ChristineDirector | PPurchaseCommon Stock,$.01 par value | +27.7K | $2.71 | +$75.0K | +12.2%254.5K after | |
| Mar 1, 2022 (view filing) | Feb 28 | 1 day | Grancio JenniferDirector | PPurchaseCommon Stock,$.01 par value | +110.7K | $2.71 | +$300.0K | +82.5%244.8K after | |
| Aug 27, 2021 (view filing) | Aug 27 | Same day | Thomson DavidEVP Genl Counsel & Secretary | SSaleCommon Stock, $.01 Par Value | −4.10K | $4.64 | −$19.0K | −0.7%567.4K after | |
| Aug 2, 2021 (view filing) | Jul 30 | 3 days | Tross Stuart AChief People & Workpl Officer | PPurchaseCommon Stock, $0.01 Par Value | +4.48K | $2.99 | +$13.4K | +0.7%634.7K after | |
| Aug 2, 2021 (view filing) | Jul 30 | 3 days | Binder Steven B.Chief Financial Officer | PPurchaseCommon Stock, $0.01 Par Value | +748 | $2.99 | +$2.24K | +0.1%547.6K after | |
| Aug 2, 2021 (view filing) | Jul 30 | 3 days | Galindo AlejandroChief Commercial Officer | PPurchaseCommon Stock, $0.01 Par Value | +5.00K | $2.99 | +$14.9K | +0.9%547.6K after | |
| Aug 2, 2021 (view filing) | Jul 30 | 3 days | Castagna MichaelChief Executive Officer | PPurchaseCommon Stock, $0.01 Par Value | +5.00K | $2.99 | +$14.9K | +0.3%1.54M after |